X-BODY is a privately held biotechnology company formed in 2008 by industry veterans Richard Wagner, Brant Binder and Gordon Binder. The company's mission is to apply its innovative capabilities to the discovery of human antibodies against high-value therapeutic targets. X-BODY has entered into a number of alliances with other corporations to generate antibody therapeutic candidates. X-BODY's internal efforts are focused on discovering and developing compounds against biologically relevant targets in oncology and ophthalmology.
x.ai was founded in 2014 by former Visual Revenue (Predictive Analytics software acquired by Outbrain) CEO Dennis R. Mortensen and his co-founders Alex Poon and Matt Casey. The wider founding team are industry veterans from analytics, big data and the predictive modeling world.
X2IMPACT is a Seattle-based technology company developing impact monitoring systems designed to provide real time, high quality information about head impact events that cause sports brain injury (SBI). The X2IMPACT Shock Sensing Mouth Guard System incorporates an array of sensors into form-fit mouth guards that report linear and rotational acceleration levels via wireless communication to sideline display devices. The system's cloud-based software then analyzes, tracks and reports potential SBI impact events in real time, placing them in context of the individual player's recent impact history to help coaches, trainers, and parents better understand and manage youth athletes' brain health. X2IMPACT'S mission is to provide useful, affordable product systems to help stop the epidemic of SBI in youth, high school and NCAA contact sports.
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and increase the ability for T-Cells to track and destroy cancer cells. The company's oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in promoting the immunosuppressive and pro-angiogenic microenvironment of many cancers. X4P-001, the company's lead program, is expected to enter Phase 1/2 testing in refractory clear cell renal cell carcinoma (ccRCC) and other solid tumor indications, and its second program, X4P-002, is in pre-clinical development for oncology applications. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.
xAd is the global location marketplace bringing together buyers and sellers with ad targeting solutions focused on driving in-store traffic and sales. The company is uniquely focused on capturing in-store visitation behaviors for ad targeting, insights, and measurement solutions. The first to visualize real-time foot traffic, xAd customers include 1.5 million advertisers - including direct brand relationships, agencies, ad networks, and other demand side media companies.
Xamarin's mission is to make it fast, easy and fun to build amazing, native mobile apps. Xamarin's cross-platform, mobile app development software allows developers to use their existing skills and tooling to build fully native apps for iOS, Android and Windows Phone, while sharing up to 90 percent of source code across device platforms. Indie developers, contract teams and enterprise organizations use Xamarin to accelerate and simplify the creation of high-performance, native consumer and corporate applications.
Xangati is the recognized leader for cloud and workload performance management solutions. Over 300 customers among enterprises, government agencies, healthcare organizations, educational systems and cloud providers use Xangati's solutions to gain unprecedented performance management of their cloud and VDI environments. Xangati's solutions built on patented technology proactively track the health of key IT metrics that impact the performance of applications and users, accurately diagnose the cause of any performance bottleneck and recommend remedial action when a bottleneck is discovered. Organizations like Ebay, Comcast, British Gas, Guess, Colliers International, Univita Health, Harvard University and the US Army use the Xangati Management Dashboard suite of solutions with its massively scalable live and continuous recording ability to ensure their business-critical applications perform at optimal levels.
Xapo has been described by The Wall Street Journal as the Fort Knox of bitcoin storage, so if you™re looking to secure your bitcoins then look no further than the Xapo Vault. We™ve developed a new standard of bitcoin security and fully insure your assets in the Vault so that you can rest assured your money is safe and sound.
XAPPmedia is the leader in interactive audio advertising and is the first company to Give Consumers a Voice allowing instant connections with brands through mobile audio apps. XAPP Ads present branded content followed by an opportunity for consumers to interact with ads by voice to receive more content, be connected directly with offers or get back to more listening. Unlike other mobile ad formats, XAPP Ads are effective even when consumers are ultramobile, which means they are listening but cannot interact with a mobile screen visually or by touch. The immediate voice conversion opportunity brings more value to advertisers and increases ad unit yield for audio app publishers. XAPPmedia was founded in 2012 and is headquartered in Washington, DC.
Xcalar is the first business analytics platform to enable Fundamental Discovery of meaningful insights directly from petabytes of raw data. Xcalar uniquely extends relational compute on a scale-out platform for modern data, allowing businesses to discover insights simply not possible otherwise. Xcalar's unprecedented speed, scale, simplicity, and efficiency bring orders of magnitude reduction in the time needed to gain business insights regardless of the size and complexity of the dataset. Xcalar does not require any data prep or data shuffling before it begins analysis, nor does it need to move data due to its patent-pending True Data In Place technology. Xcalar delivers the fastest time-to-insight on the market.
Xceedium is the leading provider of Zero Trust privileged identity and access management solutions. Xceedium products are used by large enterprises and global government agencies to meet stringent security and compliance requirements. Xceedium's world-class technology allows organizations to control access to their networks based on the user. It also contains the user to explicit resources, which eliminates the risk of allowing untrusted third parties and privileged users on networks. The company's technology secures and enforces policies for privileged user and application-to-application passwords.
Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. Xceleron pioneered the use of human microtracer and AMS and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland.
XCOR Aerospace is a California corporation located in Mojave, California. The company is in the business of developing and producing safe, reliable and reusable rocket powered vehicles, propulsion systems, advanced non-flammable composites and other enabling technologies. XCOR is working with aerospace prime contractors and government customers on major propulsion systems, and concurrently building the Lynx, a piloted, two-seat, fully reusable, liquid rocket powered vehicle that takes off and lands horizontally. The Lynx-family of vehicles serves three primary missions depending on their specific type including: research & scientific missions, private spaceflight, and micro satellite launch (only on the Lynx Mark III). The Lynx production models (designated Lynx Mark II) are designed to be robust, multi-mission (research / scientific or private spaceflight) commercial vehicles capable of flying to 100+ km in altitude up to four times per day and are being offered on a wet lease basis.
Xcovery Vision is an ophthalmology-focused subsidiary of Xcovery Holdings, a clinical-stage company developing novel therapies for cancer and inflammatory diseases. Xcovery Vision's goal is to develop innovative therapies to address unmet healthcare needs and improve the standard of care in the field of ophthalmology. Xcovery Vision is developing a comprehensive pipeline of ophthalmology therapies that target basic mechanisms of eye disease, including angiogenesis, fibrosis and inflammation.
XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMapÂ® Molecular Expression Testing, an FDA- cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. AlloMap is marketed directly by XDx in the United States and has received marketing authorization in the European Union. Some of the AlloMap technology may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system, and XDx is currently developing a lupus flare predictor test in collaboration with LabCorp. XDx's non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.
Xealth is a digital health prescribing platform that enables clinicians to easily integrate, prescribe and monitor digital health tools for patients from their EHR workflows. These can include patient education, online third-party apps and programs, device monitoring, and non-clinical services such as ride shares, food delivery and e-commerce product recommendations. Using the Xealth platform, care teams and physicians can monitor patient engagement and analyze the effects of more engaged patients. Xealth spun out of Providence St. Joseph Health in 2017, raising $8.5 million from a variety of investors including Threshold Ventures (formerly DFJ Venture), Providence Ventures and other health systems such as UPMC and Froedtert Medical College of Wisconsin Health Network.
XebiaLabs is the leading global provider of automation software for DevOps and Continuous Delivery helping companies to accelerate the delivery of new software. XebiaLabs\' products provide the automation, efficiency and insight organizations need to meet the demand for faster software deployment cycles. Founded in 2008 and headquartered in Boston, XebiaLabs has a worldwide network of sales offices and partners.
Founded in 2014, Xeeva is a global provider of intelligent cloud-based procurement software and financial solutions for indirect spend and MRO. Used in over 45 countries and available in 18 languages, their software suite automates the source-to-pay process with open communication for e-invoicing, procurement, and sourcing. Xeeva's innovative and patented technology is driven by advanced artificial intelligence and simplifies the procure-to-pay process with a focus on driving results - leading to increased productivity, improved compliance and control, and a sustainable bottom line impact.
Xenex's patented pulsed xenon Full Spectrum UV room disinfection system is a pesticidal device used for the advanced cleaning of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The Xenex mission is to eliminate harmful bacteria, viruses and spores that can cause hospital acquired infections in the patient environment, and to become the new standard method for disinfection in healthcare facilities worldwide.
Xeris is an Austin, Texas-based, specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The company's proprietary XeriSol(TM) and XeriJect(TM) formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-inject formulations of peptides, proteins, antibodies and small molecules using auto-injectors, multi-dose pens and pumps. Xeris' proprietary formulation platforms have the potential to offer distinct advantages over existing products and formulations including: up to 1000-fold lower injection volumes, long term room-temperature stability, elimination of reconstitution and refrigeration, all of which can lead to products that are easier to use by patients, caregivers, health practitioners, and can reduce costs for payers and the healthcare system.
Xfire connects more than six million hardcore gamers every month with a social gaming experience. More than 20 million gamers have downloaded the Xfire client, which supports more than 2,500 video games, and allows gamers to socially share video, pictures and conversations among friends or the entire Internet. Xfire has headquarters in Santa Monica, Calif. and Shanghai.
Xignite, Inc. provides cloud-based financial market data APIs to help emerging companies and established enterprises deliver real-time and reference market data to their digital assets, such as websites and mobile apps. Xignite's clients include more than 1,000 financial services, media and software companies from disruptive fintech firms, such as Betterment, FutureAdvisor, Motif Investing, Personal Capital, Robinhood, StockTwits, Wealthfront and Yodlee, to leading financial institutions, exchanges and market data vendors.
Xirrus is the leading provider of high-performance wireless networks. Xirrus' Array-based solutions perform under the most demanding circumstances with wired-like reliability and superior security. The Xirrus wireless solutions provide a vital strategic business and IT infrastructure advantage to the education, healthcare, government and enterprise industries that depend on wireless to operate business-critical applications.
XL Hybrids designs, manufactures and installs hybrid electric powertrains for commercial vans and trucks. The company's patent-pending hybrid electric powertrain can be installed on existing vehicles or as an upfit on new ones. By storing energy wasted in braking and reapplying it during acceleration, XL Hybrids technology decreases fuel use and carbon dioxide emissions by up to 21.2 percent on urban routes, while operating with the same durability and reliability as traditional vans and trucks.
XLerant is a software solutions company that builds and implements innovative, practical, and incredibly powerful corporate budget preparation software for mid-sized and large organizations, energizing a 'Culture of Budget Accountability' among users. The company serves clients in several industries, including higher education. XLerant's premiere budgeting and planning application, BudgetPak, replaces spreadsheet-based budgeting and provides maximum user flexibility and financial controls. Improved communication, greater ownership of the numbers and increased transparency enables companies to better manage financial performance throughout the fiscal year.
Xlumena is the leader in developing products that enable advanced image-guided endoscopy procedures. These innovations will allow endoscopists to offer minimally invasive alternatives to patients suffering from common gastrointestinal and biliary conditions. Pioneering interventional endoscopists around the world are using Xlumena's products to extend their therapeutic reach.
Xnor.ai has pioneered a lightweight AI framework that enables deep learning, machine vision, and speech recognition to be done directly on devices.
XOEye is pioneering a renaissance in the way manufacturing, industrial and widely distributed organizations operate with its industrial-grade wearable technology solutions. It combines wearable computing devices with a custom-fit operating system and cloud-based software for an end-to-end solution that provides a real-time technology solutions for both employee and customer. Business processes including training, remote support, sales, service and auditing can now be fully supported remotely while improving productivity, efficiency, and service quality. XOEye's XOLinux operating system and cloud-based XOEye Vision application suite are accessible through its open API and developer portal, offering enterprises access to these applications.
Xola provides a comprehensive cloud-based software that makes it simple for businesses to manage reservations in real time from any channel -- bookings made in-person, on Xola vendor mobile apps, over the phone, through their company website, local resellers, and through online travel agents that are integrated with Xola.
Xometry, founded in the fall of 2013, is committed to bringing manufacturing back to America by using software to build a robust and scalable manufacturing program. Xometry employs a machine-learning approach to offer its customers the optimal manufacturing solution at the best price.
Based in Boston, MA, Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with the founding scientists and entrepreneurs of new ventures to support their vision while allowing a more efficient development model to benefit company founders and early equity holders.
XOR Data Exchange, the nation's first permission-based data exchange, is leading a data revolution by giving control back to data owners. Its patent-pending permission-based data exchanges enable multiple, non-linear data-sharing relationships across competing and non-competing companies and industries, ensuring transparency and accountability among data owners while adding significant monetary value to previously under-optimized data.
Xperiel brings the Real World Web (RWW) to life. The RWW is where the physical and digital worlds converge to provide mixed reality experiences for consumers across any OS or mobile device. To orchestrate the RWW, the inventors of Google Wallet technology built the Xperiel platform, comprised of a universal trigger fabric, device-agnostic applications in the cloud and an all new graphical programming language based on the founders' original Ph.D. research. Xperiel makes it possible for users to quickly build device-agnostic applications in the cloud that are contextually aware and can communicate with real world and online triggers. A trigger is an activation point that signals Xperiel to deliver immersive, customized experiences to individuals via their mobile phones, wearables, virtual reality technology or any connected device. Xperiel's patented, easy-to-use graphical programming language opens the door for non-technical people to develop applications in less than an hour, radically compressing the time and cost it takes to build IoT apps. Xperiel changes the way people can and will interact with a completely connected world. Companies in industries spanning professional sports, entertainment, retail and more are using the Xperiel platform to maximize the value of their IoT investments.
XtalPi is a pharmaceutical technology company that is reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi's ID4 platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide.
Xtelligent Media, LLC is an online media company focused on providing intelligence and insight on the Information Technology (IT) challenges facing the healthcare industry. Our series of microsites seek to educate and provide news and intelligence to CIOs, CMIOs, HIM Directors, CFOs and other IT Professionals and staff within the healthcare industry.
Xtime is the leading cloud-based Customer Relationship Management (CRM) and scheduling platform for automotive manufacturers and dealer service departments. Xtime counts more than 4,800 dealerships as customers and has registered almost 2 million consumers. It processes more than 1.3 million appointments each month and has scheduled almost 50 million in total.
xtraCHEF is a cloud-based restaurant management platform that enables foodservice operators to maximize profits and productivity. Leveraging a combination of machine learning, data science, and quality control, xtraCHEF provides the power of data and automation to streamline the supply chain. By automating time-consuming tasks related to ordering, accounts payable, budgets, and cost management, xtraCHEF helps restaurant groups to build back-of-house operations that can scale.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company's proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit's compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance.